Houston software company looks to grow its workforce internationally

Staffing up

This growing Houston company is providing industrial industries with smart analytics. Getty Images

A Houston-based analytics-focused company is gearing up for growth in 2019 and plans to staff up its headquarters and remote offices abroad.

Arundo Analytics Inc. brings industrial companies — which sometimes are slow to adopt brand-new technology — into the world of machine learning and advanced analytics to help boost revenue, cut costs and reduce risks.

The startup's enterprise software gives asset-heavy industrial businesses "a virtual window into their day-to-day operations," says Stuart Morstead, co-founder and chief operating officer of Arundo. Among the operations that benefit from software are equipment maintenance, safety, logistics and scheduling.

Morstead points out that most industrial companies that encounter issues with operations such as equipment maintenance "lack the data science and software capabilities to drive value from insights into their daily operations."

Arundo aims to solve that problem by incorporating machine learning and advanced analytics — the kind of innovations emanating from the likes of Amazon, Google, and IBM — into everyday business operations at industrial companies, says Morstead, a former partner at consulting firm McKinsey & Co. and a graduate of Rice University.

Aside from its broad enterprise software, Arundo supplies out-of-the-box applications that tackle individual industrial challenges like flow metering for the offshore oil and gas industry and monitoring the condition of equipment. The virtual cloud-based multiphase flow meter is sold as part of a software package from industrial technology giant ABB.

More than 50 of Arundo's estimated 110 employees work on that technology from the startup's headquarters in downtown Houston. To propel its growth, Arundo plans to add employees this year in Houston as well as its other offices in Canada, Norway, Sweden and the United Kingdom, according to Morstead.

In 2016, Arundo graduated from Stanford University's StartX accelerator program. A year later, Arundo was named to the MIT STEX25 accelerator program by the Massachusetts Institute of Technology Startup Exchange.

Since its founding in 2015, Arundo has raised more $35 million in capital, including a Series A round of $28 million that closed in the first half of 2018. Investors include Sundt AS, Stokke Industri, Horizon, Canica, Strømstangen, Arctic Fund Management, Stanford-StartX Fund and Northgate Partners.

Aside from drawing more funding in 2018, the startup set up several strategic partnerships designed to increase the adoption of Arundo's software in sectors such as oil and gas, manufacturing, shipping, construction and maritime. Among the new partners are Dell Technologies, DNV GL's Veracity platform and WorleyParsons.

Going forward, Morstead says Arundo aims to bring its software expertise, business prowess and "world-class data science" to even more industrial companies and their physical assets as part of the global Industrial Internet of Things sector. That market is projected to approach $1 trillion by 2025, up from $100 billion in 2016.

To be sure, Arundo is competing in a market that's rife with opportunity. Consulting firm Accenture estimates the IIoT market could add $14.2 trillion to the global economy by 2030.

"Arguably the biggest driver of productivity and growth in the next decade, the Industrial Internet of Things will accelerate the reinvention of sectors that account for almost two-thirds of world output," the Accenture report says.

Tor Jakob Ramsøy, founder and CEO of Arundo, certainly grasps the enormous potential of IIoT.

"Asset-heavy companies can no longer afford to make business decisions based on an incomplete view of their organization," Ramsøy, a former McKinsey partner, said in a 2018 news release. "By combining deep data and [artificial intelligence] knowledge with decades of cumulative experience in enterprise consulting, Arundo is ushering in a new era in IIoT."

Tracking performance

Courtesy of Arundo

Arundo's Condition & Performance Monitoring Software can easily be plugged into a company's system and track its equipment using cloud technology.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

View All Listings